CA2442591A1 - Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer - Google Patents

Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer Download PDF

Info

Publication number
CA2442591A1
CA2442591A1 CA002442591A CA2442591A CA2442591A1 CA 2442591 A1 CA2442591 A1 CA 2442591A1 CA 002442591 A CA002442591 A CA 002442591A CA 2442591 A CA2442591 A CA 2442591A CA 2442591 A1 CA2442591 A1 CA 2442591A1
Authority
CA
Canada
Prior art keywords
trans
benzodioxol
pyrrolidine
carboxylic acid
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442591A
Other languages
English (en)
French (fr)
Inventor
Amitabh Singh
Robert J. Padley
Talat Ashraf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Amitabh Singh
Robert J. Padley
Talat Ashraf
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Amitabh Singh, Robert J. Padley, Talat Ashraf, Abbott Laboratories filed Critical Amitabh Singh
Publication of CA2442591A1 publication Critical patent/CA2442591A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002442591A 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer Abandoned CA2442591A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/832,752 2001-04-11
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
US10/118,486 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (1)

Publication Number Publication Date
CA2442591A1 true CA2442591A1 (en) 2002-10-31

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002442591A Abandoned CA2442591A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Country Status (10)

Country Link
EP (1) EP1379238A1 (pt)
JP (1) JP2005503339A (pt)
CN (1) CN1514727A (pt)
AR (1) AR033465A1 (pt)
BR (1) BR0205970A (pt)
CA (1) CA2442591A1 (pt)
IL (1) IL158071A0 (pt)
MX (1) MXPA03009277A (pt)
PE (1) PE20021032A1 (pt)
WO (1) WO2002085351A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL342500A1 (en) * 1997-08-04 2001-06-04 Abbott Lab Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Also Published As

Publication number Publication date
JP2005503339A (ja) 2005-02-03
BR0205970A (pt) 2003-09-30
PE20021032A1 (es) 2002-11-12
WO2002085351A1 (en) 2002-10-31
AR033465A1 (es) 2003-12-17
CN1514727A (zh) 2004-07-21
EP1379238A1 (en) 2004-01-14
MXPA03009277A (es) 2004-03-10
IL158071A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
US11191757B2 (en) Combination of pimavanserin and cytochrome P450 modulators
EP1602369B1 (en) Bupropion Metabolites for treating anxiety
JP5699152B2 (ja) リジン特異的デメチラーゼ−１阻害剤およびその使用
HUE034890T2 (hu) Malononitrilaminok alkalmazása neuropathiás fájdalomban
JP4823894B2 (ja) 新規水溶性プロドラッグ
TNSN07361A1 (en) 3,4-substituted pyrrolidine derivatives for the treatment of hypertension
US11337937B2 (en) TARR receptor agonists for sexual dysfunction
US20200038350A1 (en) Chemical modulators of signaling pathways and therapeutic use
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
KR20180021117A (ko) 아르기나제 활성 억제를 위한 조성물 및 방법
US10953000B2 (en) Combination of pimavanserin and cytochrome P450 modulators
WO2006125621A8 (en) Substituted piperidines as renin inhibitors
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
KR20160085917A (ko) 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
US20030092757A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
JP4610480B2 (ja) ２，６−ジ置換スチリルを有する含窒素ヘテロ環誘導体
GB0428250D0 (en) Organic compounds
JP2024041835A (ja) 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法
CA2442591A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
JP2004513885A5 (pt)
CA3231467A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors
UA96282C2 (ru) 3,5-замещенные пиперидины как ингибиторы ренина
JP2018537526A (ja) ボルテゾミブ複合体及びその使用方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued